Search Results for "treatment guidelines"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for treatment guidelines. Results 441 to 450 of 453 total matches.
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
Opioids for Pain
A new CDC guideline for prescribing opioids for pain
recently became available.1 ...
A new CDC guideline for prescribing opioids for pain
recently became available. Nonopioid drugs for pain
were reviewed in a previous issue.
Safety of Long-Term PPI Use
The Medical Letter on Drugs and Therapeutics • Aug 14, 2017 (Issue 1527)
is generally used for initial treatment of
GERD. Higher or more frequent doses may be needed for patients ...
Proton pump inhibitors (PPIs), which are used for
treatment of gastroesophageal reflux disease (GERD)
and for prevention of upper gastrointestinal adverse
effects caused by NSAIDs and aspirin, are one of
the most commonly prescribed classes of drugs in
the US. All PPIs are similarly effective and generally
well tolerated, but their long-term use has been
associated with a number of safety concerns.
Recommendations addressing these concerns have
recently been published.
OTC Drugs for Seasonal Allergies
The Medical Letter on Drugs and Therapeutics • Apr 22, 2019 (Issue 1570)
al. Treatment of seasonal allergic rhinitis: an
evidence-based focused 2017 guideline update. Ann ...
Patients with seasonal allergies often experience
nasal itching and congestion, sneezing, rhinorrhea,
and itchy, watery eyes. Oral, intranasal, and ophthalmic
preparations are widely available over the counter
(OTC) for relief of symptoms. Prescription products for
management of allergic rhinitis and allergic conjunctivitis
are reviewed separately.
Insect Repellents
The Medical Letter on Drugs and Therapeutics • Jul 07, 2025 (Issue 1732)
)
HOMS Bite Blocker BioUD Insect Repellent
and Clothing Treatment
7.75% pump spray 5 hours ▶ Repels ...
The Centers for Disease Control and Prevention
(CDC) and the Environmental Protection Agency (EPA)
recommend using insect repellents to avoid being
bitten by mosquitoes, ticks, and other arthropods
that transmit disease-causing pathogens. Repellents
applied to exposed skin should be used in conjunction
with other preventive measures such as wearing long-sleeved
shirts, pants, and socks and avoiding outdoor
activities during peak mosquito-biting times. Some
insect repellents are listed in Table 1.
Med Lett Drugs Ther. 2025 Jul 7;67(1732):105-9 doi:10.58347/tml.2025.1732a | Show Introduction Hide Introduction
Drugs for Smoking Cessation
The Medical Letter on Drugs and Therapeutics • Jul 15, 2019 (Issue 1576)
of treatment is not clear; most patients
should receive at least 3-6 months of effective therapy ...
Smoking tobacco remains the primary preventable
cause of death in the US. Smoking cessation often requires
both pharmacotherapy and behavioral support.
Drugs for Dementia
The Medical Letter on Drugs and Therapeutics • Mar 30, 2026 (Issue 1751)
are FDA-approved for treatment of
AD dementia. Rivastigmine is also approved for
treatment of dementia ...
Alzheimer's disease (AD) is the most common cause
of dementia, but cognitive decline also occurs in
other neurological conditions, such as Parkinson's
disease, Lewy body dementia, vascular dementia, and
frontotemporal dementia.
Med Lett Drugs Ther. 2026 Mar 30;68(1751):49-56 doi:10.58347/tml.2026.1751a | Show Introduction Hide Introduction
Drugs for Anxiety Disorders
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023 (Issue 1682)
classes are used for treatment of anxiety
disorders, but only a small number of randomized
comparative ...
Anxiety disorders (generalized anxiety disorder,
panic disorder, social anxiety disorder, and various
phobias) are the most common form of psychiatric
illness. They can be treated effectively with cognitive
behavioral therapy (CBT) and/or pharmacotherapy.
Med Lett Drugs Ther. 2023 Aug 7;65(1682):121-8 doi:10.58347/tml.2023.1682a | Show Introduction Hide Introduction
Nonopioid Drugs for Pain
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022 (Issue 1645)
Nonopioid Drugs for Pain
Nonopioid drugs can be used in the treatment of
many nociceptive ...
Nonopioid drugs can be used in the treatment of
many nociceptive and neuropathic pain conditions.
For severe pain, especially severe chronic cancer
pain, use of opioids may be necessary. Noninvasive
nonpharmacologic treatments, including physical
and psychological therapies, have been shown to
improve pain and function in patients with some
common chronic pain conditions and are unlikely
to cause serious harms. A multimodal approach to
analgesic therapy can increase pain control while
reducing opioid use and adverse effects.
Drugs for ADHD
The Medical Letter on Drugs and Therapeutics • Sep 01, 2025 (Issue 1736)
persists into adulthood.1 Pharmacologic treatment
of ADHD has been associated with reduced risks ...
Attention-deficit/hyperactivity disorder (ADHD) is a
common chronic neurodevelopmental disorder often
diagnosed in school-age children that frequently
persists into adulthood.Pharmacologic treatment
of ADHD has been associated with reduced risks of
substance abuse, criminal behavior, unintentional
injuries, serious traffic accidents, and all-cause
mortality. Drugs approved by the FDA for treatment
of ADHD are listed in Table 1.
Med Lett Drugs Ther. 2025 Sep 1;67(1736):137-44 doi:10.58347/tml.2025.1736a | Show Introduction Hide Introduction
Drugs for Migraine
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
Drugs for Migraine
DRUGS FOR ACUTE TREATMENT
An oral nonopioid analgesic is often sufficient ...
An oral nonopioid analgesic is often sufficient for
acute treatment of mild to moderate migraine pain
without severe nausea or vomiting. A triptan is the
drug of choice for treatment of moderate to severe
migraine in most patients without vascular disease.
Treatment of pain when it is still mild to moderate in
intensity improves headache response and reduces
the risk of recurrence.
Med Lett Drugs Ther. 2023 Jun 12;65(1678):89-96 doi:10.58347/tml.2023.1678a | Show Introduction Hide Introduction
